2026-09-03 8-K filing
8-K: Item 1.02, Item 2.01, Item 3.01, Item 3.03 2026-09-02 Trading halt
Halt: pending info request D1 +0.0%
14 earlier events › 2026-08-12 Analyst
BTIG downgrades to Neutral D1 -0.1% · +5d +0.1%
2026-08-12 8-K filing
8-K: Item 5.02, Item 5.07 D1 -0.1% · +5d +0.1%
2026-08-12 Analyst Bear
Analyst Downgrades Apogee Therapeutics Multiple analyst downgrades on Aug 12 draw market attention
D1 -0.1% · +5d +0.1%
2026-08-10 Earnings
Earnings report D1 -0.1% · +5d +0.0%
2026-08-10 Capital Bull
AbbVie to acquire Apogee for $135.11/share cash, ~$10.9B equity value Acquisition at significant premium; positive Phase 2 APEX data adds strategic value
D1 -0.1% · +5d +0.0%
2026-08-10 Analyst
CalSTRS raises Apogee stake by 24.1% Institutional quarterly increase signals long-term interest, routine 13F filing
D1 -0.1% · +5d +0.0%
2026-08-10 8-K filing
8-K: Item 2.02, Item 9.01 D1 -0.1% · +5d +0.0%
2026-07-31 Earnings
AbbVie posts $16.99 billion in Q2 revenue, trims full-year EPS guide to $13.87-$14.07 Skyrizi and Rinvoq keep driving growth as acquisition-related expenses reshape the earnings outlook.
D1 -0.2% · +5d +0.6%
2026-06-20 → 07-13 Capital Bull
AbbVie's $10.9B Apogee Acquisition Details Continue to Emerge CEO disposes shares via gift and sale amid ongoing deal
D1 +46.7% · +5d +0.0%
› 5 waves of this story2026-06-20 FT reports near all-cash deal at ~60% premium to bolster anti-inflammatory portfolio2026-06-23 Deal valued at ~$10.9B, 49.5% premium, deepens immunology portfolio2026-06-24 Post-deal analyst downgrade reflects adjusted expectations amid certainty2026-07-03 Merger doc shows CDAs with AbbVie and parties A-C from Mar-May; Party A signals unlikely to participate2026-07-13 CEO disposes shares via gift and sale amid ongoing deal2026-06-24 Analyst
4 analyst rating changes (0 up / 4 down) D1 -0.1% · +5d +0.1%
2026-06-23 Analyst
4 analyst rating changes (0 up / 4 down) D1 +0.2% · +5d -0.1%
2026-06-22 8-K filing
8-K: Item 1.01, Item 5.07, Item 7.01, Item 8.01 D1 +46.7% · +5d +0.0%
2026-06-22 Insider selling Bear
Insider selling $14.1M (2) D1 +46.7% · +5d +0.0%
2026-06-22 Analyst Bear
Canaccord Genuity downgrades to Hold D1 +46.7% · +5d +0.0%
by direction · sourced
Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice
be the first
🙂 Post
Facts and opinions separated · All items sourced · Not investment advice
